BamSEC and AlphaSense Join Forces
Learn More

Interpace Biosciences Inc.

OTC: IDXG    
Share price (11/21/24): $2.68    
Market cap (11/21/24): $11.8 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 36 pages Asset Purchase Agreement
12/34/56
EX-2.1
from 10-Q 15 pages Asset Purchase Agreement for New Haven Laboratory Between Interpace Biosciences, Inc. and Diamir Biosciences, Corp
12/34/56
EX-2
from SC 13D/A 14 pages Secured Promissory Note
12/34/56
EX-2
from SC 13D/A 5 pages Support Agreement
12/34/56
EX-2.1
from 8-K 84 pages Secured Creditor Asset Purchase Agreement by and Among Interpace Biopharma, Inc. as the Buyer, Partners for Growth IV, L.P. as the Seller and Cancer Genetics, Inc. and Interpace Diagnostics Group, Inc. (Solely for Purposes of the Specified Sections) Dated as of July 15, 2019
12/34/56
EX-2.1
from DEFA14A 85 pages Asset Purchase Agreement by and Between Publicis Touchpoint Solutions, Inc., and Pdi, Inc. Dated October 30, 2015 Asset Purchase Agreement
12/34/56
EX-2.1
from 8-K 85 pages Asset Purchase Agreement by and Between Publicis Touchpoint Solutions, Inc., and Pdi, Inc. Dated October 30, 2015 Asset Purchase Agreement
12/34/56
EX-2.3
from 10-K 146 pages Agreement and Plan of Merger by and Among Redpath Integrated Pathology, Inc., Pdi, Inc., Interpace Diagnostics, LLC, Redpath Acquisition Sub, Inc. and Redpath Equityholder Representative, LLC as Equityholder Representative, October 31, 2014
12/34/56
EX-2.2
from 10-Q 139 pages Asset Purchase Agreement by and Between Asuragen, Inc. and Interpace Diagnostics, LLC Dated as of August 13, 2014
12/34/56
EX-2.1
from 10-K 18 pages Asset Purchase Agreement
12/34/56
EX-2
from 8-K >50 pages Plan of reorganization, merger, acquisition or similar
12/34/56
EX-2.1
from 8-K ~50 pages Agreement and Plan of Merger
12/34/56
EX-2.1
from S-1/A ~5 pages Plan of reorganization, merger, acquisition or similar
12/34/56